Literature DB >> 25440959

Dysplastic nevi, cutaneous melanoma, and other skin neoplasms in patients with myotonic dystrophy type 1: a cross-sectional study.

Anna Zampetti1, Gabriella Silvestri2, Simona Manco3, Katy Khamis3, Marcella Masciullo4, Maria Laura Ester Bianchi2, Antonello Damiani5, Massimo Santoro6, Dennis Linder7, Anthony Bewley8, Claudio Feliciani9.   

Abstract

BACKGROUND: Myotonic dystrophy type 1 (MD1) is reported to be associated with internal malignancies. The association of myotonic dystrophy with cutaneous tumors is not fully understood.
OBJECTIVE: We sought to explore the total nevi count and the presence of atypical nevi, cutaneous melanoma, and other skin neoplasms in a representative cohort of patients with MD1 and to compare the findings with age- and sex-matched control subjects.
METHODS: In all, 90 patients with MD1 and 103 age- and sex-matched control subjects were assessed for cutaneous neoplasms by clinical skin and epiluminescence examination (dermoscopy). Where indicated, subsequent excisions were performed. In patients with MD1, leukocyte n(CTG) expansion was measured.
RESULTS: Patients with MD1 showed significantly higher numbers of nevi, dysplastic nevi, and melanomas despite a significantly greater proportion of the control subjects reporting sunburns. In addition, we found a significantly greater number of pilomatrixoma in patients with MD1. LIMITATIONS: Our study is limited by the fact that there is no agreed-upon standardized technique to assess for prior sun exposure. Further research in the association of cutaneous neoplasms and MD1 including vitamin D and molecular biological techniques are also recommended.
CONCLUSION: MD1 itself may predispose to development of skin tumors.
Copyright © 2014 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Steinert disease; dermoscopy; dysplastic nevus; melanoma; myotonic dystrophy; nonmelanoma skin cancer; pilomatrixoma; skin cancer

Mesh:

Year:  2014        PMID: 25440959     DOI: 10.1016/j.jaad.2014.09.038

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

1.  Pigmentation phenotype, photosensitivity and skin neoplasms in patients with myotonic dystrophy.

Authors:  S M Gadalla; J E Hilbert; W B Martens; S Givens; R T Moxley; M H Greene
Journal:  Eur J Neurol       Date:  2017-03-20       Impact factor: 6.089

2.  Multiple basal cell carcinomas in a patient with myotonic dystrophy type 1.

Authors:  Jessica Feng; Avery LaChance; David A Sinclair; Maryam M Asgari
Journal:  BMJ Case Rep       Date:  2019-03-08

3.  Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research Datalink.

Authors:  Youjin Wang; Ruth M Pfeiffer; Rotana Alsaggaf; Wilhelmine Meeraus; Julia C Gage; Lesley A Anderson; Renée C Bremer; Nikoletta Nikolenko; Hanns Lochmuller; Mark H Greene; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2017-11-20       Impact factor: 7.396

4.  A population-based survey of risk for cancer in individuals diagnosed with myotonic dystrophy.

Authors:  Diana Abbott; Nicholas E Johnson; Lisa A Cannon-Albright
Journal:  Muscle Nerve       Date:  2016-07-07       Impact factor: 3.217

5.  Benign tumors in myotonic dystrophy type I target disease-related cancer sites.

Authors:  Rotana Alsaggaf; Diane Marie M St George; Min Zhan; Ruth M Pfeiffer; Youjin Wang; Lesley A Anderson; Zhiwei Liu; Jill Koshiol; Andrew J Bauer; Kathryn R Wagner; Mark H Greene; Sania Amr; Shahinaz M Gadalla
Journal:  Ann Clin Transl Neurol       Date:  2019-07-26       Impact factor: 4.511

6.  Brain tumors in patients with myotonic dystrophy: a population-based study.

Authors:  S M Gadalla; R M Pfeiffer; S Y Kristinsson; M Björkholm; O Landgren; M H Greene
Journal:  Eur J Neurol       Date:  2015-10-28       Impact factor: 6.089

7.  Hemangiomas of the tongue and the oral cavity in a myotonic dystrophy type 1 patient: A case report.

Authors:  Simona Portaro; Antonino Naro; Claudio Guarneri; Giuseppe Di Toro; Alfredo Manuli; Rocco Salvatore Calabrò
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

8.  Mutation analysis of multiple pilomatricomas in a patient with myotonic dystrophy type 1 suggests a DM1-associated hypermutation phenotype.

Authors:  Albert Rübben; Renate Ursula Wahl; Thomas Eggermann; Edgar Dahl; Nadina Ortiz-Brüchle; Claudio Cacchi
Journal:  PLoS One       Date:  2020-03-10       Impact factor: 3.240

9.  Ki67/MART1 and p63/SOX10 Dual Immunohistochemistry Allows a Correct Interpretation of the Melanocytic Component in the Diagnosis of Pigmented Pilomatricoma.

Authors:  Serena Ammendola; Elena Bariani; Vassilena Tsvetkova; Paolo Gisondi; Paolo Rosina; Ilaria Girolami; Michele Coato; Matteo Brunelli; Albino Eccher; Chiara Colato
Journal:  Indian J Dermatol       Date:  2021 Sep-Oct       Impact factor: 1.494

10.  No Evidence of Abnormal Expression of Beta-Catenin and Bcl-2 Proteins in Pilomatricoma as One Clinical Feature of Tetrasomy 9p Syndrome.

Authors:  Chariyawan Charalsawadi; Sasipong Trongnit; Kanoot Jaruthamsophon; Juthamas Wirojanan; Somchit Jaruratanasirikul; Anupong Nitiruangjaras; Pornprot Limprasert
Journal:  Int J Pediatr       Date:  2021-12-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.